8-K: Disc Medicine Advances Pipeline, Bitopertin NDA Accepted

Disc Medicine provides positive updates on its clinical pipeline, including Bitopertin's NDA acceptance and promising Phase 2 data for DISC-0974 in anemia of myelofibrosis.

Summary

• Bitopertin's New Drug Application (NDA) has been accepted by the FDA on November 28, with an anticipated action date by the end of January 2026.
• Bitopertin was selected for the FDA's Commissioners National Priority Voucher (CNPV) Pilot Program, which is expected to lead to faster review times (1-2 months) and potential accelerated approval.
• Initial Phase 2 RALLY-MF data for DISC-0974 in anemia of myelofibrosis (MF) showed consistent decreases in hepcidin and increases in serum iron, along with positive, durable benefits on hemoglobin and transfusion burden.
• DISC-0974 demonstrated clinically meaningful improvements in fatigue and achieved overall response rates of 63-71% across various MF patient cohorts, regardless of concomitant JAK inhibitor use.
• Phase 2 study for DISC-3405 in polycythemia vera (RESTORE-PV) initiated in June 2025 and has expanded due to rapid enrollment, with initial data expected in H2 2026.
• A Phase 1b study for DISC-3405 in sickle cell disease (SCD) initiated in October 2025, with initial data also expected in H2 2026.
• The company is funded into 2029, supporting potential Bitopertin commercialization and several key pipeline milestones.

Sentiment

Score: 9

Explanation: The filing presents highly positive updates across the company's key pipeline assets, including a significant regulatory milestone (Bitopertin NDA acceptance and CNPV designation), strong clinical data for DISC-0974, and rapid progress for DISC-3405. The company's robust cash runway into 2029 further de-risks its operational plans. No negative news or delays were reported.

Positives

• Bitopertin NDA accepted by FDA on November 28, indicating regulatory progress.
• Bitopertin's inclusion in the FDA's CNPV Pilot Program suggests a faster review timeline (1-2 months) and potential for accelerated approval.
• Anticipated Bitopertin action date by end of January 2026, with drug supply availability expected concurrently.
• DISC-0974 Phase 2 RALLY-MF data shows consistent and substantial hepcidin suppression and iron increase, leading to positive, durable benefits on hemoglobin and transfusion burden in anemia of MF.
• DISC-0974 demonstrated clinically meaningful improvements in fatigue (FACIT-Fatigue score) in MF patients.
• High overall response rates (63-71%) and major response rates (50-71%) for DISC-0974 in nTD and TD Low MF cohorts, with similar responses regardless of concomitant JAK inhibitor therapy.
• DISC-3405 Phase 2 study in polycythemia vera (RESTORE-PV) is rapidly enrolling and has been expanded, indicating strong interest and progress.
• DISC-3405 Phase 1b study in sickle cell disease has been initiated.
• The company has a strong cash position, funded into 2029, providing runway for commercialization and pipeline development.

Negatives

• No significant negative results or setbacks were reported in the filing.

Risks

• The adequacy of capital to support future operations and successfully initiate and complete clinical trials.
• Difficulty in predicting the time and cost of developing product candidates.
• Plans to research, develop, and commercialize current and future product candidates may not be realized as expected.
• The timing of initiation of planned preclinical studies and clinical trials may be delayed.
• The timing of the availability of data from clinical trials may be uncertain.
• Ability to identify additional product candidates with significant commercial potential and expand the pipeline in hematological diseases.
• The risk that results from preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval.

Future Outlook

The company anticipates a potential Bitopertin approval and launch by the end of January 2026, benefiting from the FDA's CNPV program for accelerated review. For DISC-0974, pivotal trial initiation is expected in H1 2027 following topline Phase 2 data and an EOP2 meeting in H2 2026. A Phase 2 study for anemia of IBD is expected to start in early 2026. Initial data for DISC-3405's Phase 2 PV study and Phase 1b SCD study are both expected in H2 2026. The company is well-funded into 2029, supporting these upcoming milestones and potential commercialization.

Management Comments

• Disc is committed to ensuring access to bitopertin for patients as quickly as possible and is advancing commercial readiness activities to support potential launch of bitopertin on accelerated timeline, if approved. (John Quisel, JD, PhD, Chief Executive Officer)
• Initial RALLY-MF data supports DISC-0974 target profile in anemia of MF; planning to advance to pivotal study following Ph 2 topline and EOP2 meeting with FDA. (John Quisel, JD, PhD, Chief Executive Officer)
• First in-patient studies for DISC-3405 are underway in PV and SCD with data expected in 2026. (John Quisel, JD, PhD, Chief Executive Officer)
• Company is funded into 2029, well into potential bitopertin commercialization and several key pipeline milestones. (John Quisel, JD, PhD, Chief Executive Officer)

Industry Context

Disc Medicine operates in the hematology space, targeting high unmet medical needs such as erythropoietic porphyrias, anemia of myelofibrosis, polycythemia vera, and sickle cell disease. The company's strategy involves developing differentiated product profiles, with Bitopertin poised for potential accelerated approval, and DISC-0974 and DISC-3405 addressing significant market opportunities with novel mechanisms. The MF anemia market alone is estimated at over $2 billion in the US, indicating substantial commercial potential for DISC-0974. The competitive landscape for MF anemia is described as 'thinning,' positioning DISC-0974 as a potential primary therapy. For PV and SCD, DISC-3405 aims to offer improved treatment options where current therapies are suboptimal or limited.

Comparison to Industry Standards

• DISC-0974's initial ORR of 63-71% and MRR of 50-71% across MF cohorts are presented as superior response rates compared to current off-label anemia therapies, though specific comparative data or competitor names are not provided in the filing.
• For Polycythemia Vera, current treatments offer suboptimal HCT control, leading to increased risk of thrombotic events. DISC-3405's target profile of monthly subcutaneous dosing with favorable safety/tolerability and no injection site reactions to-date aims to offer a differentiated profile compared to existing options.
• For Sickle Cell Disease, the historical use of phlebotomy to reduce symptoms provides evidence for the potential of iron restriction, suggesting DISC-3405 could offer a novel disease-modifying therapy where limited effective treatment options exist.

Stakeholder Impact

• Shareholders: Positive news regarding regulatory progress, strong clinical data, and extended cash runway could lead to increased investor confidence and potential share price appreciation.
• Patients: Potential for new, effective treatments for serious hematological disorders like erythropoietic porphyrias, anemia of myelofibrosis, polycythemia vera, and sickle cell disease, with Bitopertin potentially available by early 2026.
• Employees: Continued progress and strong financial position provide stability and opportunities for growth.
• Healthcare Providers: New therapeutic options could become available to address significant unmet needs in hematology, offering better outcomes for patients.

Next Steps

• Collaborate with FDA throughout the ongoing review process for Bitopertin.
• Continue accelerated activities to support a potential US approval and launch of Bitopertin by end of January 2026.
• Drive enrollment of the ongoing APOLLO confirmatory trial for Bitopertin in US, UK, Canada, Australia, and Europe.
• Share further details on Bitopertin commercialization and launch planning at the JP Morgan Healthcare Conference in January 2026.
• Initiate Phase 2 study for DISC-0974 in anemia of IBD early 2026 (Q1 2026).
• Conduct IND-enabling activities for long-acting anti-HJV (DISC-0998).
• Expect Phase 2 data for DISC-0974 in H2 2026.
• Hold an EOP2 meeting for DISC-0974 in H2 2026.
• Initiate pivotal trial for DISC-0974 in H1 2027, pending regulatory feedback.
• Expect initial RESTORE-PV Phase 2 data for DISC-3405 in H2 2026.
• Expect initial Phase 1b data for DISC-3405 in Sickle Cell Disease in H2 2026.

Key Dates

Recommendation

The filing contains multiple highly positive catalysts: Bitopertin's NDA acceptance and CNPV designation significantly de-risk its path to market with an accelerated timeline for potential approval and launch by January 2026. The strong interim Phase 2 data for DISC-0974 in a large, underserved market (anemia of MF) demonstrates clear efficacy and safety, positioning it for pivotal trials. Furthermore, DISC-3405 is progressing well in two additional indications with significant market potential. The company's robust cash runway into 2029 provides financial stability to execute on these milestones. These combined factors suggest a strong growth trajectory and significant upside potential, warranting a 'strong buy' recommendation.

Keywords

Disc Medicine, Bitopertin, DISC-0974, DISC-3405, SEC filing, 8-K, NDA acceptance, FDA CNPV, Accelerated approval, Erythropoietic Porphyrias, Anemia of Myelofibrosis, Polycythemia Vera, Sickle Cell Disease, Hematology, Clinical trials, Phase 2 data, Drug development, Biotechnology, Pharmaceuticals